Education
About Us
Working with TipRanks
Follow Us
Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
OTLC Stock Chart & Stats
$0.08
>-$0.01(-12.62%)
At close: 4:00 PM EST
$0.08
>-$0.01(-12.62%)
Day’s Range― - ―
52-Week Range$0.03 - $0.11
Previous CloseN/A
Volume643.67K
Average Volume (3M)410.07K
Market Cap
$33.19M
Enterprise Value$48.52M
Total Cash (Recent Filing)$409.00K
Total Debt (Recent Filing)$17.41M
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Apr 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding442,596,600
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-19.12
Enterprise Value/Market Cap1.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-56.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Management Incentive AlignmentTying CEO equity vesting to conversion/repayment milestones aligns leadership incentives with balance-sheet repair and deleveraging. Over months this should focus management on securing durable financing, reducing leverage, and executing capital-structure fixes that improve long-term financial flexibility and governance.
Proprietary Data Platform LaunchLaunching PDAOAI establishes a durable non-clinical asset that can drive partnerships, dataset licensing, and translational research engagement. A platform that extracts biological signals without bespoke LLM training can become a sustainable competitive advantage supporting R&D productivity and collaborations over the medium term.
Completed Convertible Financings With Registration RightsRefinancing prior notes and issuing convertible two-year notes with registration rights extends runway and improves investor protections. This durable funding step reduces near-term maturity pressure and provides optionality for financing execution while management advances clinical or platform milestones.
Bears Say
Pre-revenue With Persistent LossesThe company remains effectively pre-revenue with ongoing operating losses, leaving no internal revenue engine to fund R&D or operations. Over the next several months this limits self-sufficiency, forces continued external capital needs, and keeps profitability distant absent clear clinical or commercial progress.
Elevated Leverage For StageMeaningful debt relative to equity increases financial risk for a low-revenue biotech: higher fixed obligations limit flexibility, raise refinancing risk, and can constrain strategic choices. Over a 2–6 month horizon elevated leverage amplifies vulnerability to failed financings or adverse cash-flow swings.
Ongoing Reliance On Dilutive FinancingThe company's repeated use of convertible notes and equity-linked financings creates structural dilution risk and ongoing dependency on capital markets. Over months this can erode shareholder value, complicate capital structure, and make long-term planning contingent on successful, potentially dilutive financings or asset monetizations.
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.03 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $33.19M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is Apr 20, 2026 which is in 74 days.
How were Oncotelic Therapeutics’s earnings last quarter?
Oncotelic Therapeutics released its earnings results on Nov 24, 2025. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.002.
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 442,596,600 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Oncotelic Therapeutics reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.301%.
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---